cFluor® V547 Anti-Human CD20 (2H7)
The 2H7 monoclonal antibody binds to human CD20, a 33-37 kDa, four-transmembrane phosphoprotein. CD20 is present on all stages of B cell development except for early pro-B cells or plasma cells to play a role in B-cell activation, proliferation and differentiation1. In some studies, CD20 is thought to act as a Ca2+ channel in the plasmas membrane2. It is also present on a T cell subset at low levels as well as some follicular dendritic cells. The antibody was conjugated to a fluorophore and puriﬁed by afﬁnity chromatography.
Format: cFluor® V547*
Isotype: Mouse IgG2b, κ
Tested Dilution: 5 μL / test
Application: Flow Cytometry
Storage: 2-8°C and protected from Light. Do not freeze
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% BSA (Origin USA)
Each lot of this antibody is quality control tested using flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per 1 million cells in a staining volume of 100 µL. If whole blood is analyzed, then use 5 µL per 100 µL. It is recommended that users titrate the antibody to obtain the optimal result for their specific application.
- Tedder TF, et al. 1994. Immunol Today. 15(9):450–4
- Putney JW Jr. 1999. Proc Natl Acad Sci USA. 96(26):14669-14671
For Research Use Only. Not intended for use in diagnostic procedures.
*cFluor™ V547 is equivalent to CF®405L manufactured and provided by Biotium, Inc. under an Agreement between Biotium and Cytek (LICENSEE). The manufacture, use, sale, offer for sale, or import of the product is covered by one or more of the patents or pending applications owned or licensed by Biotium. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel.